European Archives - Page 53 of 1556 - European Medical Journal

AI Shows Promise in Radiotherapy-Associated CVT – EMJ

AI Shows Promise in Radiotherapy-Associated Cardiovascular Toxicity

AI shows promise for radiotherapy-associated cardiovascular toxicity, a major concern for cancer survivors, a new systematic review has found.

New Research Reveals How E. coli Persists from Farm to Table

Environmental E. coli isolated from lettuce, soil, and irrigation water displayed multiple stress-adaptation traits that may enhance persistence and complicate food safety measures.

EASL 2026 Interview: Sven Francque

I think we should go back a little bit to the pathophysiology of the disease, because this is largely driven by extrahepatic…

Androgen Deprivation Therapy Choice in Prostate Cancer

Androgen deprivation therapy (ADT) has long been the cornerstone of treatment for advanced prostate cancer. Since the…

MHRA issues warning against promoting unlicensed drugs

A joint warning has been issued against promoting newly licensed prescription-only and unlicensed medicines for weight management.

UNICEF and Gavi call to accelerate Bundibugyo vaccine access

UNICEF and Gavi have made a call to manufacturers to accelerate access to a Bundibugyo vaccine, amid the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda.

FDA Clears First Over-the-Counter CGM for Children

The US FDA has cleared for marketing the first over-the-counter continuous glucose monitor for children.

Gut Interoception Predicts Relapse in Anorexia Nervosa

New research links disrupted gut interoception to relapse risk in weight-restored anorexia nervosa, suggesting ingestible probes could become biomarkers.

25 Jun 2026

Biomarkers & Beyond: Diagnosing Alzheimer’s

Explore how to integrate clinical and biomarker assessments to make an accurate diagnosis of Alzheimer’s disease in the earliest stages, and..

Single-Fraction SBRT Shows Promise as Treatment for Prostate Cancer

Single-fraction SBRT achieved promising 3-year cancer control with low toxicity in selected men with localised prostate cancer, according to a phase 1/2 trial.